Nyxoah Launches Game-Changing Genio Therapy in Middle East
Nyxoah Unveils Genio Therapy in the Middle East
Nyxoah, a pioneering medical technology company based in Belgium, has announced the exciting commercial launch of its Genio system, designed to provide a groundbreaking approach to treating Obstructive Sleep Apnea (OSA) through advanced neuromodulation. This significant event marks a major milestone for OSA treatment within the Middle East, particularly highlighted by the first successful Genio implant performed at the renowned Saudi German Hospital in Dubai.
Significant Milestone for OSA Treatment
The first patient receiving the Genio implant was a celebrated occasion, executed by Dr. Ahmed Yassin Bahgat, a Consultant Otolaryngologist at the hospital. Dr. Bahgat expressed pride in being part of this innovative shift in healthcare, stating, “Offering Genio therapy to OSA patients is an honor. This device represents a clinically proven and intelligent solution for those who struggle with CPAP treatment.” This perspective captures the essence of Genio’s value to patients.
Visionary Leadership and Commitment
Olivier Taelman, the CEO of Nyxoah, shared his views regarding the launch: “Genio entering the UAE market is a game-changing moment as it is the first neurostimulation therapy available for Obstructive Sleep Apnea within the region. We take immense pride in providing a patient-focused solution that brings hope to OSA patients who experience discomfort with CPAP devices.” His commitment reflects Nyxoah's broader vision of expanding access to innovative treatments globally.
Transforming Patient Experiences
Nyxoah continues to revolutionize treatment approaches for the one billion individuals worldwide suffering from obstructive sleep apnea. The Genio system, a notable advancement, is designed as a battery-free hypoglossal neuromodulation device that is strategically inserted through a single incision beneath the chin. The therapy’s controllable nature via a wearable device is a testament to its user-friendly design. By adhering to rigorous clinical standards and showing promising treatment outcomes, Nyxoah aims to set a new industry benchmark.
A Legacy of Innovation
The successful pilot, known as the BLAST OSA study, was a critical stepping stone in Nyxoah’s journey, facilitating the acquisition of the European CE Mark in 2019. With a mission that aligns with enhancing the lives of patients struggling with OSA, Nyxoah has showcased its commitment not only through innovative device development but also via successful public offerings on Euronext Brussels and NASDAQ.
Heading Towards Future Developments
Recently, positive results from the BETTER SLEEP study enabled Nyxoah to expand its CE mark approval to include patients with Complete Concentric Collapse (CCC), an area often deemed a limitation by competing therapies. Such advancements significantly ensure that Nyxoah remains at the forefront of OSA treatment innovation. Furthermore, the promising data from the DREAM IDE pivotal study signals strong potential for FDA approval and subsequent U.S. commercialization.
Contacting Nyxoah
For further inquiries regarding this groundbreaking launch, individuals can contact Nyxoah through their investor relations email at IR@nyxoah.com. Additionally, for media-related queries in Belgium/France, Backstage Communication’s Gunther De Backer is available at gunther@backstagecom.be. For international or German inquiries, one can reach out to MC Services’ Anne Hennecke at nyxoah@mc-services.eu.
Frequently Asked Questions
What is the Genio system?
The Genio system is a battery-free hypoglossal neuromodulation device designed to treat Obstructive Sleep Apnea by promoting ease of breathing during sleep.
Where has the Genio system been launched?
Genio has recently been commercialized in the Middle East, initially marked by its first successful implantation in Dubai.
Who performed the first Genio implant?
The first implant was conducted by Dr. Ahmed Yassin Bahgat at Saudi German Hospital in Dubai.
What makes Genio different from CPAP?
Genio offers a less intrusive alternative to CPAP for OSA patients, focused on comfort and usability without the need for continuous external devices.
What are Nyxoah's future plans?
Nyxoah aims to expand its therapeutic offerings while pursuing FDA approval for the Genio system in the U.S. market, increasing accessibility for more patients.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.